Clinical Trials
340 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
MK-3475-G21
Merck Sharp & Dohme LLC
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
PRIMAVERA
AstraZeneca
MK-3475-051
Merck Sharp & Dohme LLC
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
DAHLIA
Recursion Pharmaceuticals Inc.
MAPtivate-6
Pfizer
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Fujifilm Pharmaceuticals U.S.A., Inc.
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Hangzhou Hanx Biopharmaceuticals, Ltd.
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
OPAL
AVM Biotechnology Inc
CPIT001
Hackensack Meridian Health
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
QUADvance
AvenCell Therapeutics, Inc.
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
ALPHA2
Allogene Therapeutics
CAVALRY
University of Chicago
HeartPhone Cancer Survivors Trial 2019
Penn State University
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd.
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
SELECT-CAR-NK
Essen Biotech
PlaTform
The Lymphoma Academic Research Organisation
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Sheba Medical Center
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Evopoint Biosciences Inc.
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd